Research Paper Volume 12, Issue 6 pp 4794—4814

The LSD1 inhibitor iadademstat (ORY-1001) targets SOX2-driven breast cancer stem cells: a potential epigenetic therapy in luminal-B and HER2-positive breast cancer subtypes

Figure 2. Iadademstat suppresses mammosphere formation in a basal-like established cell line. Figure shows representative microscope representations (×2.5 magnification) of mammospheres formed by MDA-MB-436 cells growing in sphere medium for 6 days in the absence or presence of graded concentrations of iadademstat. The number of mammospheres (>100 μm diameter) is expressed as means (columns) ± SD (bars). MTT uptake-based measurement of cell viability is expressed as percentages uptake (OD570) relative to untreated controls (=100% cell viability). The results are expressed as percentages means (columns) ± SD (bars). *P < 0.05 and **P < 0.005, statistically significant differences from the untreated (control) group.